

Market Commentary

Major equity indices sold off in March. The S&P 500 suffered its biggest monthly decline since December 2022, dropping 5.6%. European equity markets also fell sharply, with the Euro STOXX 50, Germany DAX, and FTSE 100 total return indices returning -3.8%, -1.7%, and -2.0%, respectively over March. Trump 2.0 policy uncertainty was the main factor behind the continued deterioration in performance during the month, with tariff uncertainty also behind the pickup in inflation expectations seen in consumer surveys. At its March meeting, the U.S. Federal Reserve kept the target range for the federal funds rate unchanged at 4.25%-4.50%, noting that inflation remains somewhat elevated and uncertainty around the economic outlook has increased. Utilities (+1.5%) was the only positive S&P/ASX 300 sector over the month, while Information Technology (-9.1%), Consumer Discretionary (-6.2%), and A-REIT (-4.8%) were the worst performing sectors.

Fund Update and Outlook

The Hyperion Australian Growth Companies Fund returned -8.6% (net of fees) in March, underperforming its benchmark (S&P/ASX 300 Accumulation Index) by 5.2%. James Hardie Industries PLC, Pro Medicus Ltd and Lovisa Holdings Ltd saw the largest share price declines, while Cochlear Ltd saw a small positive performance. Volatility and uncertainty continued to dominate financial markets throughout the month as market participants speculated on the effects of U.S. tariffs. Broad-based U.S. tariffs may have a modest short-term inflationary impact on consumers via higher-priced tangible products, which may slow real economic growth rates. Hyperion believes this will have little impact on the ability of our portfolio companies to grow earnings in the long run due to their strong value propositions and significant pricing power. Our portfolio companies have shown that they are resilient in a rising price environment, which can be evidenced over the past three to four years. We remain positive about the long-term return outlook for our Domestic Strategy. Recent reporting season results have been broadly consistent and supportive of our long run valuations and expected future returns. Opportunities can often appear when financial markets disconnect from fundamentals (signals) and trade on fear and speculation (noise). Read more [here](#).

The Hyperion Asset Management team is pleased to announce we have been named 2025 Overall Fund Manager of the Year at the Morningstar Awards for Investing Excellence in Australia. Along with the Overall Fund Manager of the Year award, Hyperion was also recognised in three other Morningstar category awards, including:

- 2025 Fund Manager of the Year – Global Equities (Hyperion Global Growth Companies Fund – Active ETF)
- 2025 Fund Manager of the Year – Domestic Equities – Large Cap (Hyperion Australian Growth Companies Fund)
- 2025 Fund Manager of the Year - Domestic Equities – Small Cap (Hyperion Small Growth Companies Fund)

The recognition is a testament to our disciplined proprietary investment process which has demonstrated how skilled bottom-up long-term structural growth investing can generate superior long-term performance. 2025 is the fourth time Hyperion has been named the Morningstar Overall Fund Manager of the Year (previously in 2024, 2021 and 2016). You can learn more about the Morningstar Awards [here](#).

Please consider the Product Disclosure Statement (PDS) of the Fund, which provides more complete information on risks and fees, in its entirety and Target Market Determination (TMD) before making an investment decision. The current PDS and TMD of the Fund can be found at <https://www.hyperion.com.au/>. Companies mentioned are illustrative only and not a recommendation to buy or sell any particular security.

Objective

Long-term capital growth by investing in high-calibre Australian companies primarily listed within the S&P/ASX 300 at the time of investment.


Our Philosophy

The highest proven quality businesses with the strongest competitive advantages and organic growth opportunities produce superior shareholder returns over the long term.

We believe companies in our portfolio have:

- Earnings which will grow or be maintained
- Low debt
- High interest cover
- Sustainable competitive advantages
- High return on capital
- Strong free cash flow
- Organic growth options
- Experienced and proven management teams

Growth of \$10,000 Since Inception, Post-Fees



Inception date: 30th September 2002. Source: Hyperion Asset Management. Past performance is for illustrative purposes only and is not indicative of future performance.

Fund Performance

	Portfolio – Net (%)	Benchmark ¹ (%)	Excess Performance (%)
1 Month	-8.6	-3.3	-5.2
3 Month	-15.2	-2.9	-12.4
1 Year	-0.7	2.6	-3.4
3 Year (p.a.)	4.5	5.3	-0.8
5 Year (p.a.)	11.5	13.2	-1.7
7 Year (p.a.)	10.7	8.6	2.1
10 Years (p.a.)	8.9	7.1	1.7
15 Years (p.a.)	9.3	7.5	1.7
20 Years (p.a.)	10.2	7.7	2.6
Inception (p.a.)*	11.0	8.8	2.2
Inception (TR)*^	949.3	573.8	375.5

1. S&P/ASX 300 Accumulation Index. *Inception date that Hyperion became Investment Manager: 30th September 2002. ^Total return. All p.a. returns are annualised. Returns are net of applicable fees and costs. Past performance is not a reliable indicator of future performance. Data as at 31st March 2025. Due to rounding, excess performance figures may not equate perfectly to the difference between Hyperion Australian Growth Companies Performance and the S&P/ASX 300 Accumulation Index Performance.

Top 5 Holdings

	Portfolio (%)	Benchmark (%)
Xero Limited	10.3	0.9
Block, Inc.	8.4	0.2
Wisetech Global Ltd	7.6	0.6
Fisher & Paykel Healthcare Corporation Ltd	7.5	0.2
Cochlear Limited	7.3	0.7

Companies shown are illustrative only and not a recommendation to buy or sell any particular security.

Sector Allocation

	Portfolio (%)	Benchmark (%)
Communication Services	8.2	3.9
Consumer Discretionary	7.8	7.9
Financials	20.2	32.9
Health Care	33.3	9.8
Industrials	1.0	7.6
Information Technology	22.1	3.0
Materials	3.5	19.2
Real Estate	2.2	6.7
Cash	1.7	--

Portfolio weights may not sum perfectly to 100.0% due to rounding.

Market Capitalisation (AUD)

	Pf (%)	Bm (%)	Act. (%)	# Stocks
S&P/ASX 1-20	18.5	59.9	-41.4	4
S&P/ASX 21-50	41.2	17.4	23.8	9
S&P/ASX 51-100	29.8	11.8	18.0	6
S&P/ASX 101-200	8.1	8.0	0.1	4
S&P/ASX 201-300	0.7	2.9	-2.2	1
Ex S&P/ASX 300	--	--	--	--
Cash	1.7	--	1.7	--
Total	100	100	--	24

Portfolio weights may not sum perfectly to 100.0% due to rounding.

Top Contributors and Detractors (rolling 12 months)

Contributors	Price change (%)	Avg Weight (%)	Contribution to return (%)
Fisher & Paykel Healthcare Corporation Ltd	27.9	7.8	2.3
Pro Medicus Ltd	92.6	1.8	1.4
HUB24 Ltd	60.8	3.4	1.3
Resmed, Inc.	16.0	6.7	1.2
Technology One Ltd	64.1	2.9	1.1

Detractors	Price change (%)	Avg Weight (%)	Contribution to return (%)
Block, Inc.	-33.0	9.9	-4.7
James Hardie Industries	-37.5	3.1	-1.5
Cochlear Ltd	-22.3	7.0	-1.4
Domino's Pizza Enterprises Ltd	-41.1	2.5	-1.1
IDP Education Ltd	-47.5	1.3	-0.7

Companies shown are illustrative only and not a recommendation to buy or sell any particular security.

Fund Characteristics

Universe	S&P/ASX 300
Launch	Managed by Hyperion since September 2002, launched October 1996
Risk/Return Profile	The Fund's risk band is 7 (very high)
Fees	MER 0.95%
Distribution	AUD 1.3594 CPU at 30 September 2024 AUD 4.6618 CPU at 30 June 2024 AUD 0.1283 CPU at 31 March 2024 AUD 0.0619 CPU at 31 December 2023
Fund Size	\$2,273.8 million
APIR Code	BNT0003AU

The Fund's PDS contains more complete information on risks and fees

All data as at 31st March 2025



CERTIFIED BY RIAA

RIAA Certified Fund

The Hyperion Australian Growth Companies Fund has been certified by the Responsible Investment Association Australasia (RIAA) according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See www.responsiblereturns.com.au for details and the last page of this document for disclaimers.

Portfolio Holdings Update

Pro Medicus Ltd (PME-AU)

Primary Exchange

ASX

GICS Sector

Health Care

Market Cap (\$m)

20,872



Pro Medicus Ltd. (PME) reported a record 1H25 result at top and bottom lines, with revenue of A\$97.2m (+31% yoy) and EBITDA of A\$69.9m (+42.9% yoy). The result was driven largely by the continued rapid growth of its Visage product suite in North America (A\$86.4m 1H25 revenue, +34.6% yoy). During the half year, PME won key contracts with Trinity Health, Lurie Children's Hospital and Duly Health and Care. These contracts were for a combined minimum amount of A\$365m over 7-10-year deals. In addition, PME renewed contracts with Mercy Health in the USA (A\$98 million, 8 years) and with a large Australian radiology practice (A\$32 million, 5 years). The company noted a strong sales pipeline across all market segments within its core radiology vertical, and a more conservative outlook for its new cardiology product. We expect PME to sustain a solid deal cadence driven by hospital cloud migrations and acute radiologist shortages which drive demand for its market-leading Visage products.

Wisetech Global Ltd (WTC-AU)

Primary Exchange

ASX

GICS Sector

Information Technology

Market Cap (\$m)

27,169



Wisetech Global Ltd. (Wisetech) released its HY25 results. The company reported Cargowise organic revenue of +20% driven by new large freight forwarder customer rollouts and existing customer growth. Wisetech signed Cargowise deals with two new Top 25 global freight forwarders in the half, taking the total to 14 customers of the Top 25 global freight forwarders. We believe this reflects the strong value proposition of the Cargowise platform, which provides a depth and breadth of functionality tailored to freight forwarders that is unmatched by competitors. The company grew reported EBITDA by +28%, as a result of gross margin improvement and good cost discipline, partially offset by continued investment into product development to drive future growth. While it is disappointing that the timing of releases of new products has been pushed out, we remain confident in the value proposition of these products. We await an update from the company on the appointment of independent directors to the board and an update on management succession planning.


CONTACT US

HYPERION DISTRIBUTION


Jolon Knight
Mob: 0414 805 862
Jolon.knight@hyperion.com.au

INVESTOR SERVICES

Tel: 1300 497 374
Investorservices@hyperion.com.au



Awarded Fund Manager of the Year – Overall
Morningstar 2025 Awards, Australia.




Awarded Fund Manager of the Year – Overall
Morningstar 2024 Awards, Australia.



Awarded Fund Manager of the Year – Overall
Morningstar 2021 Awards, Australia.



Awarded Fund Manager of the Year – Domestic Equities Large Cap Category
Morningstar 2021 Awards, Australia.



Awarded Fund Manager of the Year – Domestic Equities Large Cap Category
Morningstar 2020 Awards, Australia.

DISCLAIMER – HYPERION AUSTRALIAN GROWTH COMPANIES FUND

This communication is prepared by Hyperion Asset Management Limited (ABN 80 080 135 897 AFSL 238 380) ('Hyperion'), as the investment manager of the Hyperion Australian Growth Companies Fund (ARSN 089 548 443) ('the Fund'). Pinnacle Fund Services Limited (ABN 29 082 494 362 AFSL 238 371) ('PFSL') is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund is available at <https://www.hyperion.com.au/>. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund. For historic TMD's please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com.

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Unless otherwise specified, all amounts are in AUD. Due to rounding, numbers presented throughout this report may not sum precisely to the total indicated and performance percentages may not precisely reflect the absolute returns.

Whilst Hyperion, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Hyperion, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Hyperion and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Hyperion. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

This may contain the trade names or trademarks of various third parties, and if so, any such use is solely for illustrative purposes only. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and Hyperion.

Morningstar Awards 2025 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Australian Growth Companies fund for Fund Manager of the Year – Domestic Equities – Large Cap, Australia.

Awarded to Hyperion Small Growth Companies fund for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Awarded to Hyperion Global Growth Companies fund for Fund Manager of the Year – Global Equities , Australia

Morningstar Awards 2024 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Small Growth Companies fund for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Morningstar Awards 2021 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for Overall Fund Manager of the Year, Australia.

Awarded to Hyperion Asset Management for for Fund Manager of the Year – Domestic Equities – Large Cap

Awarded to Hyperion Asset Management for for Fund Manager of the Year - Domestic Equities - Small Caps, Australia.

Morningstar Awards 2020 ©. Morningstar, Inc. All Rights Reserved.

Awarded to Hyperion Asset Management for for Fund Manager of the Year – Domestic Equities – Large Cap

The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

Hyperion neither provided nor was given compensation in relation to the above-mentioned award/s, however Hyperion pays a licensing fee in order to be able to display awards' logos. Disclaimers specific to awards received by Hyperion can be viewed at: <https://www.hyperion.com.au/awards-and-ratings>